{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:55:25Z","timestamp":1781643325652,"version":"3.54.5"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer immunotherapy is a broad term including naked antibodies, bispecific antibodies (BsAbs), immune-checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR-T) therapy, cancer vaccines, activated immune cells, and allogeneic hematopoietic cell transplantation. Recent advances in immune-engaging T-cell therapies have led to significant progress in novel treatments across various cancer types, resulting in prolonged patient survival, mainly in patients with hematologic malignancies. Several CAR T-cell constructs and BsAbs have been approved by regulatory authorities worldwide for relapsed, refractory leukemia, non-Hodgkin lymphoma, and multiple myeloma. Solid tumors are characterized by an immunosuppressive, fibroinflammatory tumor microenvironment (TME) and immune-suppressive cells, such as regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs). This, coupled with challenges such as tumor-intrinsic factors (tumor antigen heterogeneity, target antigen loss, hypoxia within the tumor bed, and insufficient preexisting tumor-infiltrating lymphocytes [TILs]) and therapy-related hurdles like on-target off-tumor toxicity, impedes the development of durable immune-engaging T-cell therapies across solid tumor types. However, a few BsAbs, TILs, and autologous-engineered T-cell receptor (TCR) therapies have recently been approved across indications, paving the way for newer horizons in the solid tumor cellular therapy landscape. Here, we review the available data on the efficacy and safety of cellular therapies and BsAbs in solid tumors approved thus far by the U.S. Food and Drug Administration. These include BsAbs, TILs, and TCR therapy. Given the lack of homogeneous clinical practice guidelines for TCE therapies in solid tumors, we discuss and compare the efficacy and safety of five therapies. We further present the therapeutic pipeline across solid tumors and discuss strategies currently under investigation to optimize T-cell subsets to enhance antitumor efficacy while improving the safety profile.<\/jats:p>","DOI":"10.1007\/s12672-026-04802-x","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:41:54Z","timestamp":1773758514000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of approved cellular therapies and bispecific antibodies in solid tumors: the current state"],"prefix":"10.1007","volume":"17","author":[{"given":"Rabab Zehra","family":"Jafry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Bilal","family":"Qamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohaib","family":"Irfan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abbas","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Mohlere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Maithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Hassan","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan A.","family":"Vaziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"4802_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-019-0155-8","volume":"8","author":"MB Abid","year":"2019","unstructured":"Abid MB, Shah NN, Maatman TC, Hari PN. Gut microbiome and CAR-T therapy. Exp Hematol Oncol. 2019;8:31. https:\/\/doi.org\/10.1186\/s40164-019-0155-8.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"4802_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-018-0015-x","volume":"25","author":"MB Abid","year":"2018","unstructured":"Abid MB. The revving up of CARs. Gene Ther. 2018;25(3):162. https:\/\/doi.org\/10.1038\/s41434-018-0015-x.","journal-title":"Gene Ther"},{"issue":"12","key":"4802_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtct.2021.09.016","volume":"27","author":"J Meir","year":"2021","unstructured":"Meir J, Abid MA, Abid MB. State of the CAR-T: risk of infections with chimeric antigen receptor T-cell therapy and determinants of SARS-CoV-2 vaccine responses. Transplant Cell Ther. 2021;27(12):973\u201387. https:\/\/doi.org\/10.1016\/j.jtct.2021.09.016.","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"4802_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/mba2.20","volume":"1","author":"J Zhang","year":"2022","unstructured":"Zhang J, Guo Q, Wang Q, Duan Y. CD3-T-cell-engager (TCE) therapies to overcome solid tumors: beyond BiTEs. MedComm \u2013 Biomaterials and Applications. 2022;1(2):e20. https:\/\/doi.org\/10.1002\/mba2.20.","journal-title":"MedComm \u2013 Biomaterials and Applications"},{"key":"4802_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882. https:\/\/doi.org\/10.3389\/fimmu.2023.1113882.","journal-title":"Front Immunol"},{"issue":"3","key":"4802_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/bjh.19633","volume":"205","author":"AS Gonugunta","year":"2024","unstructured":"Gonugunta AS, Mohlere V, Abid MB. Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma\u2013the current state. Br J Haematol. 2024;205(3):1197\u2013201. https:\/\/doi.org\/10.1111\/bjh.19633.","journal-title":"Br J Haematol"},{"issue":"2","key":"4802_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","volume":"24","author":"BC Cho","year":"2023","unstructured":"Cho BC, Simi A, Sabari J, Vijayaraghavan S, Moores S, Spira A. Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications. Clin Lung Cancer. 2023;24(2):89\u201397. https:\/\/doi.org\/10.1016\/j.cllc.2022.11.004.","journal-title":"Clin Lung Cancer"},{"issue":"10","key":"4802_CR8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","volume":"19","author":"S Vijayaraghavan","year":"2020","unstructured":"Vijayaraghavan S, Lipfert L, Chevalier K, et al. Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis. Mol Cancer Ther. 2020;19(10):2044\u201356. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0071.","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"4802_CR9","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76(13):3942\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2833.","journal-title":"Cancer Res"},{"key":"4802_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei J, Yang Y, Wang G, Liu M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276. https:\/\/doi.org\/10.3389\/fimmu.2022.1035276.","journal-title":"Front Immunol"},{"issue":"17","key":"4802_CR11","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","volume":"29","author":"K Chon","year":"2023","unstructured":"Chon K, Larkins E, Chatterjee S, et al. FDA approval summary: Amivantamab for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. Clin Cancer Res. 2023;29(17):3262\u20136. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3713.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"4802_CR12","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1200\/JCO.21.00662","volume":"39","author":"K Park","year":"2021","unstructured":"Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391\u2013402. https:\/\/doi.org\/10.1200\/JCO.21.00662.","journal-title":"J Clin Oncol"},{"key":"4802_CR13","doi-asserted-by":"crossref","unstructured":"Lee S-H, Cho BC, Han J-Y et al. Amivantamab and lazertinib in treatment-na\u00efve EGFR-mutated advanced non\u2013small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS. presented at: 2023 ASCO Annual Meeting I. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.9134"},{"key":"4802_CR14","unstructured":"FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. US Food and Drug Administration (FDA). 2024. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications. Accessed 28 Oct 2024."},{"issue":"22","key":"4802_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389(22):2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"},{"key":"4802_CR16","unstructured":"Rybrevant\u2009+\u2009Lacluze. Johnson & Johnson. 2024. https:\/\/www.rybrevanthcp.com\/. Accessed 18 Oct 2024."},{"key":"4802_CR17","unstructured":"FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer. FDA. 11\/14\/2024. 2024. Updated 8\/20\/2024. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer. Accessed 14 Nov 2024."},{"key":"4802_CR18","unstructured":"FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations. U.S Food and Drug Administration (FDA). 2024. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19. Accessed 28 Oct 2024."},{"issue":"1","key":"4802_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.11","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol Jan. 2024;35(1):77\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.11.","journal-title":"Ann Oncol Jan"},{"key":"4802_CR20","unstructured":"Yang JC-H, Kim YJ, L S-H et al. Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC: Final Overall Survival from the Phase 3 MARIPOSA Study. Presented at European Lung Cancer Congress 2025; March 26\u201329, 2025."},{"issue":"3_Suppl 1","key":"4802_CR21","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S1556-0864(25)00199-6","volume":"20","author":"J-H Yang","year":"2025","unstructured":"Yang J-H, Kim YJ, L S-H, et al. 40: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. J Thorac Oncol. 2025;20(3_Suppl 1):S6\u20138.","journal-title":"J Thorac Oncol"},{"key":"4802_CR22","unstructured":"Amivantamab (Rx). Medscape. 2024. https:\/\/reference.medscape.com\/drug\/rybrevant-amivantamab-4000216#11. Accessed 28 Oct 2024."},{"key":"4802_CR23","doi-asserted-by":"crossref","unstructured":"Spira AI, Paz-Ares L, Han J-Y et al. Preventing Infusion-Related Reactions With Intravenous Amivantamab\u2014Results From SKIPPirr, a Phase 2 Study: A Brief Report. J Thorac Oncol. 2025.","DOI":"10.1016\/j.jtho.2025.01.018"},{"key":"4802_CR24","doi-asserted-by":"crossref","unstructured":"Girard N, Li W, Spira AI et al. Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-Mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib: Early Success of the COCOON Trial. Presented at European Lung Cancer Congress. 2025.","DOI":"10.1016\/S1556-0864(25)00205-9"},{"issue":"22","key":"4802_CR25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"issue":"3","key":"4802_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.56875\/2589-0646.1049","volume":"15","author":"A Haroon","year":"2022","unstructured":"Haroon A, Muhsen IN, Abid MB, et al. Infectious complications and preventative strategies following chimeric antigen receptor T-cells (CAR-T cells) therapy for B-cell malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):153\u20138. https:\/\/doi.org\/10.56875\/2589-0646.1049.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"4802_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738","volume":"131","author":"JM Sands","year":"2025","unstructured":"Sands JM, Champiat S, Hummel HD, et al. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer. 2025;131(3):e35738. https:\/\/doi.org\/10.1002\/cncr.35738.","journal-title":"Cancer"},{"issue":"4","key":"4802_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4802_CR29","unstructured":"Amgen presents new data for first-in-class Imdelltra\u2122 (tarlatamab-dlle) in small cell lung cancer at WCLC 2024. Amgen. 2024. https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/09\/amgen-presents-new-data-for-firstinclass-imdelltra-tarlatamabdlle-in-small-cell-lung-cancer-at-wclc-2024#:~:text=DeLLphi%2D301%20Phase%202%20Extended,population%2C%20underscoring%20its%20clinical%20significance. Accessed 18 Oct 2024."},{"key":"4802_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1643","volume":"33","author":"SM Gadgeel","year":"2022","unstructured":"Gadgeel SM, Al-Mondhiry J, Ahn MJ, et al. 1549TiP DeLLphi-303: phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE\u00ae), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC). Ann Oncol. 2022;33:S1255. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1643.","journal-title":"Ann Oncol"},{"key":"4802_CR31","unstructured":"FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. U.S Food and Drug Administration. Updated 1\/26\/2022. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma. Accessed 18 Oct 2024."},{"issue":"13","key":"4802_CR32","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"issue":"24","key":"4802_CR33","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel JC, Piperno-Neumann S, Rutkowski P, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023;389(24):2256\u201366. https:\/\/doi.org\/10.1056\/NEJMoa2304753.","journal-title":"N Engl J Med"},{"issue":"8","key":"4802_CR34","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1158\/2159-8290.CD-23-1334","volume":"14","author":"AJ Schoenfeld","year":"2024","unstructured":"Schoenfeld AJ, Lee SM, de Doger Speville B, et al. Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors. Cancer Discov. 2024;14(8):1389\u2013402. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1334.","journal-title":"Cancer Discov"},{"key":"4802_CR35","unstructured":"FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. U.S Food and Drug Administration. Updated 2\/16\/2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-lifileucel-unresectable-or-metastatic-melanoma. Accessed 18 Oct 2024."},{"key":"4802_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018962","volume":"13","author":"MH Kazemi","year":"2022","unstructured":"Kazemi MH, Sadri M, Najafi A, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: it takes two to tango? Front Immunol. 2022;13:1018962. https:\/\/doi.org\/10.3389\/fimmu.2022.1018962.","journal-title":"Front Immunol"},{"key":"4802_CR37","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944927","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV. First regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs)\u2013Lifileucel (Amtagvi). Med Sci Monit. 2024;30:e944927. https:\/\/doi.org\/10.12659\/MSM.944927.","journal-title":"Med Sci Monit"},{"key":"4802_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"4802_CR39","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39(24):2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"4802_CR40","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2024.42.16_suppl.9505","volume":"42","author":"SS Thomas","year":"2024","unstructured":"Thomas SS, Gogas H, Hong YK, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. J Clin Oncol. 2024;42(16suppl):9505\u20139505. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9505.","journal-title":"J Clin Oncol"},{"key":"4802_CR41","doi-asserted-by":"crossref","unstructured":"O\u2019Malley D, Lee S, Psyrri A et al. 492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-na\u00efve patients with advanced cancers. presented at: SITC 36th Anniversary Annual Meeting (SITC 2021). 2021.","DOI":"10.1136\/jitc-2021-SITC2021.492"},{"issue":"15suppl","key":"4802_CR42","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","volume":"37","author":"AA Jazaeri","year":"2019","unstructured":"Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37(15suppl):2538\u20132538. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2538.","journal-title":"J Clin Oncol"},{"key":"4802_CR43","doi-asserted-by":"crossref","unstructured":"Hong DS, Van Tine BA, Biswas S et al. Autologous T cell therapy for MAGE-A4\u2009+\u2009solid cancers in HLA-A*02\u2009+\u2009patients: a phase 1 trial. Nature Medicine Published January 9, 2023. Accessed 13 Oct 2025.","DOI":"10.1038\/s41591-022-02128-z"},{"issue":"10399","key":"4802_CR44","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0140-6736(23)00872-3","volume":"402","author":"MB Abid","year":"2023","unstructured":"Abid MB. The denominator in early phase CAR T-cell trials examining novel target antigens. Lancet. 2023;402(10399):354\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(23)00872-3.","journal-title":"Lancet"},{"issue":"1","key":"4802_CR45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1470-2045(21)00695-1","volume":"23","author":"MB Abid","year":"2022","unstructured":"Abid MB. Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era. Lancet Oncol. 2022;23(1):16\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(21)00695-1.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4802_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01115-0","volume":"14","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou AM, Van Morris K, Vo HH, et al. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. J Hematol Oncol. 2021;14(1):102. https:\/\/doi.org\/10.1186\/s13045-021-01115-0.","journal-title":"J Hematol Oncol"},{"key":"4802_CR47","unstructured":"FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma. U.S Food and Drug Administration. 2024. Updated August 2, 2024. Accessed 18 Oct 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-afamitresgene-autoleucel-unresectable-or-metastatic-synovial-sarcoma"},{"key":"4802_CR48","unstructured":"Van Tine BA, Ganjoo KN, Blay J-Y, The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma. presented at: 2023 ASCO Annual Meeting I;, May et al. 31, 2023 2023; Accessed 18 Oct 2024."},{"key":"4802_CR49","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo SP, Van Tine BA, Attia S, SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid\/round cell liposarcoma. presented at: 2021 ASCO Annual Meeting I;, May et al. 28, 2021 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.11504"},{"issue":"10435","key":"4802_CR50","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(24)00319-2.","journal-title":"Lancet"},{"key":"4802_CR51","unstructured":"D\u2019Angelo SP, Ganjoo KN, Blay J-Y et al. The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma. presented at: 2023 ASCO Annual Meeting I; 2023; Accessed 18 Oct 2024."},{"key":"4802_CR52","doi-asserted-by":"crossref","unstructured":"Wong K, Williams L, Constant N et al. ,. Abstract 297. Manufacture of KSQ-001, a CRISPR\/Cas9-engineered TIL (eTIL) therapy, for the treatment of head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 2022;10.1136\/jitc-2022-SITC2022.0297","DOI":"10.1136\/jitc-2022-SITC2022.0297"},{"key":"4802_CR53","unstructured":"KSQ Therapeutics announces. first patient dosed in phase 1\/2 study for KSQ-004EX, a CRISPR\/Cas9-engineered tumor infiltrating lymphocyte (eTIL\u00ae) therapy. News release. KSQ Therapeutics, Inc. Accessed 1 May 2025."},{"key":"4802_CR54","unstructured":"A phase 1\/2 study of KSQ-001EX. autologous tumor infiltrating lymphocytes engineered to inactivate the SOCS1 gene, in patients with select advanced solid tumors. ClinicalTrials.gov. Accessed 1 May 2025."},{"issue":"16","key":"4802_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","volume":"42","author":"RN Amaria","year":"2024","unstructured":"Amaria RN, McQuade JL, Davies MA, et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. J Clin Oncol. 2024;42(16):9515. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.9515.","journal-title":"J Clin Oncol"},{"key":"4802_CR56","unstructured":"Obsidian. Therapeutics announces FDA fast track designation for OBX-115 for the treatment of advanced melanoma. News release. Obsidian Therapeutics. Accessed 1 May 2025."},{"key":"4802_CR57","doi-asserted-by":"publisher","unstructured":"Agostinetto E, Montemurro F, Puglisi F, et al. Immunotherapy for HER2-positive breast cancer: clinical evidence and future perspectives. Cancers (Basel) Apr. 2022;25(9). https:\/\/doi.org\/10.3390\/cancers14092136.","DOI":"10.3390\/cancers14092136"},{"issue":"6","key":"4802_CR58","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","volume":"5","author":"M Hegde","year":"2024","unstructured":"Hegde M, Navai S, DeRenzo C, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880\u201394. https:\/\/doi.org\/10.1038\/s43018-024-00749-6.","journal-title":"Nat Cancer"},{"issue":"3","key":"4802_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41435-024-00275-6","volume":"25","author":"X Li","year":"2024","unstructured":"Li X, Zhao L, Li W, Gao P, Zhang N. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Genes Immun. 2024;25(3):201\u20138. https:\/\/doi.org\/10.1038\/s41435-024-00275-6.","journal-title":"Genes Immun"},{"issue":"1","key":"4802_CR60","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad024","volume":"5","author":"SS Wang","year":"2023","unstructured":"Wang SS, Davenport AJ, Iliopoulos M, et al. HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma. Neurooncol Adv. 2023;5(1):vdad024. https:\/\/doi.org\/10.1093\/noajnl\/vdad024.","journal-title":"Neurooncol Adv"},{"issue":"6","key":"4802_CR61","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","volume":"14","author":"X Qin","year":"2024","unstructured":"Qin X, Ning W, Liu H, Liu X, Luo W, Xia N. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy. Acta Pharm Sin B. 2024;14(6):2361\u201377. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.027.","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"4802_CR62","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/2159-8290.CD-21-1119","volume":"12","author":"AM Schram","year":"2022","unstructured":"Schram AM, Odintsov I, Espinosa-Cotton M, et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 2022;12(5):1233\u201347. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1119.","journal-title":"Cancer Discov"},{"key":"4802_CR63","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3389\/fimmu.2018.00814","volume":"9","author":"HH Oberg","year":"2018","unstructured":"Oberg HH, Kellner C, Gonnermann D, et al. Tribody [(HER2)(2)xCD16] is more effective than trastuzumab in enhancing gammadelta T cell and natural killer cell cytotoxicity against HER2-expressing cancer cells. Front Immunol. 2018;9:814. https:\/\/doi.org\/10.3389\/fimmu.2018.00814.","journal-title":"Front Immunol"},{"issue":"4","key":"4802_CR64","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334. https:\/\/doi.org\/10.1038\/s41591-022-01726-1.","journal-title":"Nat Med"},{"issue":"2","key":"4802_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Grullich C, et al. Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy. 2021;13(2):125\u201341. https:\/\/doi.org\/10.2217\/imt-2020-0256.","journal-title":"Immunotherapy"},{"key":"4802_CR66","doi-asserted-by":"publisher","DOI":"10.1177\/17562872231182219","volume":"15","author":"KK Zarrabi","year":"2023","unstructured":"Zarrabi KK, Narayan V, Mille PJ, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023;15:17562872231182219. https:\/\/doi.org\/10.1177\/17562872231182219.","journal-title":"Ther Adv Urol"},{"issue":"1","key":"4802_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10(1):38. https:\/\/doi.org\/10.1186\/s40364-022-00385-1.","journal-title":"Biomark Res"},{"issue":"48","key":"4802_CR68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg9721","volume":"9","author":"D Li","year":"2023","unstructured":"Li D, Guo X, Yang K, et al. Epcam-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Sci Adv. 2023;9(48):eadg9721. https:\/\/doi.org\/10.1126\/sciadv.adg9721.","journal-title":"Sci Adv"},{"issue":"1","key":"4802_CR69","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","volume":"16","author":"G Frey","year":"2024","unstructured":"Frey G, Cugnetti APG, Liu H, et al. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy. MAbs. 2024;16(1):2322562. https:\/\/doi.org\/10.1080\/19420862.2024.2322562.","journal-title":"MAbs"},{"key":"4802_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1121020","volume":"10","author":"DA Osorio-Rodriguez","year":"2023","unstructured":"Osorio-Rodriguez DA, Camacho BA, Ramirez-Segura C. Anti-ROR1 CAR-T cells: architecture and performance. Front Med (Lausanne). 2023;10:1121020. https:\/\/doi.org\/10.3389\/fmed.2023.1121020.","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"4802_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1326437","volume":"6","author":"SH Gohil","year":"2017","unstructured":"Gohil SH, Paredes-Moscosso SR, Harrasser M, et al. An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors. Oncoimmunology. 2017;6(7):e1326437. https:\/\/doi.org\/10.1080\/2162402X.2017.1326437.","journal-title":"Oncoimmunology"},{"key":"4802_CR72","doi-asserted-by":"crossref","unstructured":"Vijayaraghavan S, Winkis A, Chevalier K, Marthaler A, Sproesser K, Torti V et al. Abstract LB122: JNJ-87890387, a novel ENPP3 bispecific T-cell redirector (ENPP3xCD3) with tumor selectivity through targeting apical surface antigens presented at: AACR Annual Meeting 2024; April 5, 2024 2024; San Diego, California. Accessed 18 Oct 2024.","DOI":"10.1158\/1538-7445.AM2024-LB122"},{"issue":"11","key":"4802_CR73","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen J, Koenecke C, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med Nov. 2023;29(11):2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med Nov"},{"issue":"748","key":"4802_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl2720","volume":"16","author":"CR Stadler","year":"2024","unstructured":"Stadler CR, Ellinghaus U, Fischer L, et al. Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6. Sci Transl Med. 2024;16(748):eadl2720. https:\/\/doi.org\/10.1126\/scitranslmed.adl2720.","journal-title":"Sci Transl Med"},{"issue":"5","key":"4802_CR75","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","journal-title":"Nat Med"},{"issue":"5","key":"4802_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1135","volume":"9","author":"L Xia","year":"2020","unstructured":"Xia L, Zheng ZZ, Liu JY, et al. EGFR\u2010targeted CAR\u2010T cells are potent and specific in suppressing triple\u2010negative breast cancer both in vitro and in vivo. Clinical & Translational Immunology. 2020;9(5):e01135. https:\/\/doi.org\/10.1002\/cti2.1135.","journal-title":"Clinical & Translational Immunology"},{"key":"4802_CR77","doi-asserted-by":"crossref","unstructured":"Xie C, Mabry-Hrones D, Coffman KL, Hicks S, Redd B, Wood B et al. A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC). presented at: ASCO Gastrointestinal Cancers Symposium; January 24, 2023 2023; San Francisco, California. Accessed 18 Oct 2024.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS624"},{"issue":"4","key":"4802_CR78","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"K Du","year":"2021","unstructured":"Du K, Li Y, Liu J, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther. 2021;29(4):1572\u201384. https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.006.","journal-title":"Mol Ther"},{"key":"4802_CR79","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051357","author":"X Zhai","year":"2023","unstructured":"Zhai X, Mao L, Wu M, Liu J, Yu S. Challenges of anti-mesothelin CAR-T-cell therapy. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15051357.","journal-title":"Cancers (Basel)"},{"key":"4802_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbad014.003","author":"L Cheng","year":"2023","unstructured":"Cheng L, Zhang D, Liu W, et al. A novel MSLN\u00d74-1BB bispecific antibody for solid tumor. Antib Ther. 2023. https:\/\/doi.org\/10.1093\/abt\/tbad014.003.","journal-title":"Antib Ther"},{"issue":"1","key":"4802_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1682381","volume":"9","author":"JP Sanderson","year":"2020","unstructured":"Sanderson JP, Crowley DJ, Wiedermann GE, et al. Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology. 2020;9(1):1682381. https:\/\/doi.org\/10.1080\/2162402X.2019.1682381.","journal-title":"Oncoimmunology"},{"key":"4802_CR82","doi-asserted-by":"crossref","unstructured":"Blumenschein GR Jr., Davar D, Gutierrez R et al. A phase I\/II first-in-human study of a novel anti-MAGE-A4 TCR\/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101). presented at: 2020 ASCO Annual Meeting I; May 25, 2020; Accessed 18 Oct 2024.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3165"},{"key":"4802_CR83","doi-asserted-by":"crossref","unstructured":"Lenherr-Frey D, Vrohlings M, Bouvy-Liivrand M, In silico tumor immune microenvironment (TiME) analysis of non-small cell lung cancer (NSCLC) to inform clinical development of CDR404: A first-of-its-kind MAGE-A4 targeted T-cell engager. presented at: 2024 ASCO Annual Meeting I;, May et al. 29, 2024; Accessed 18 Oct 2024.","DOI":"10.1200\/JCO.2024.42.16_suppl.e20024"},{"key":"4802_CR84","unstructured":"Park JH, Halton EF, Diamonte CR et al. 54 - A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC). Presented at: SGO 20\/20 Vision For the Future: Annual Meeting on Women\u2019s Cancer. 2020."},{"key":"4802_CR85","doi-asserted-by":"crossref","unstructured":"Liao JB, Stanton SE, Chakiath M, Phase 1\/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients. presented at: 2023 ASCO Annual Meeting I;, May et al. 31, 2023; Accessed 18 Oct 2024.","DOI":"10.1200\/JCO.2023.41.16_suppl.5590"},{"issue":"4","key":"4802_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200868","volume":"32","author":"HK Lin","year":"2024","unstructured":"Lin HK, Blake DA, Liu T, et al. Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer. Molecular Therapy: Oncology. 2024;32(4):200868. https:\/\/doi.org\/10.1016\/j.omton.2024.200868.","journal-title":"Molecular Therapy: Oncology"},{"key":"4802_CR87","doi-asserted-by":"crossref","unstructured":"Sun J, Huang X, Qin Y et al. Abstract 2965: LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16. presented at: AACR Annual Meeting; April 4, 2023 2023; Orlando, Florida. Accessed 18 Oct 2024.","DOI":"10.1158\/1538-7445.AM2023-2965"},{"key":"4802_CR88","unstructured":"Moore KN, Bouberhan S, Hamilton EP, First-in-human phase 1\/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer. presented at: 2023 ASCO Annual Meeting I; May 31, Zhang H, Yang Z, Zhu X, Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion. presented at: 2024 ASCO Annual Meeting I;, May et al. 29, 2024 2024; Accessed 18 Oct 2024."},{"key":"4802_CR89","doi-asserted-by":"publisher","unstructured":"Segal NH, Melero I, Moreno V et al. 2024;15(1):4091. https:\/\/doi.org\/10.1038\/s41467-024-48479-8 Falchook GS, Patel MR, Ulahannan SV,. A first-in-human phase I dose-escalation trial of the B7-H6\/CD3 T-cell engager BI 765049\u2009\u00b1\u2009ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6. presented at: 2022 ASCO Annual Meeting I; June 2, 2022 2022; J Clin Oncol. Accessed 18, Oct 2024.","DOI":"10.1038\/s41467-024-48479-8"},{"key":"4802_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012391","author":"SS Pinho","year":"2025","unstructured":"Pinho SS, Macauley MS, L\u00e4ubli H. Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-012391.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"4802_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Li Z, Zhu Y, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025;6(10):100804. https:\/\/doi.org\/10.1016\/j.medj.2025.100804.","journal-title":"Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04802-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04802-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:16:23Z","timestamp":1781640983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04802-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4802"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04802-x","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"637"}}